EC Paediatrics

Short Communication Volume 12 Issue 1 - 2023

Childhood Interstitial Lung Disease: What have we Learned So Far?

Mariam Mahmoud Hassan El Makkawy1* and Safwat Hassan Gad2

1Department of Paediatrics, AIMST University, Malaysia
2Associate Professor, Department of Paediatrics, AIMST University, Malaysia

*Corresponding Author: Mariam Mahmoud Hassan El Makkawy, Department of Paediatrics, AIMST University, Malaysia.
Received: December 20, 2022; Published: December 28, 2022




Childhood interstitial lung disease (chILD) comprises > 200 rare heterogeneous respiratory disorders that can affect infants, children, and adolescents [1]. The prevalence (1.5 - 3.8 cases per million [2] and incidence (1.3 cases per million children [3]) of chILD may vary across different studies/analyses depending on study design [1].

  1. Deterding RR., et al. “Approaching clinical trials in childhood interstitial lung disease and pediatric pulmonary fibrosis”. American Journal of Respiratory and Critical Care Medicine 200 (2019): 1219-1227.
  2. Saddi V., et al. “Childhood interstitial lung diseases in immunocompetent children in Australia and New Zealand: a decade’s experience”. Orphanet Journal of Rare Diseases 12 (2017): 133.
  3. Griese M., et al. “Incidence and classification of pediatric diffuse parenchymal lung diseases in Germany”. Orphanet Journal of Rare Diseases 4 (2009): 26.
  4. Kurland G., et al. “An official American thoracic Society clinical practice guideline: classification, evaluation, and management of childhood interstitial lung disease in infancy”. American Journal of Respiratory and Critical Care Medicine 188 (2013): 376-394.
  5. Kurland G., et al. “An official American Thoracic Society clinical practice guideline: Classification, evaluation, and management of childhood interstitial lung disease in infancy”. American Journal of Respiratory and Critical Care Medicine 188 (2013): 376-394.
  6. Fan LL., et al. “Diffuse lung disease in biopsied children 2 to 18 years of age. Application of the chILD classification scheme”. Annals of the American Thoracic Society 12 (2015): 1498-1505.
  7. Deterding RR., et al. “Approaching clinical trials in childhood interstitial lung disease and pediatric pulmonary fibrosis”. American Journal of Respiratory and Critical Care Medicine 200 (2019): 1219-1227.
  8. Klusmann M and Owens C. “HRCT in paediatric diffuse interstitial lung disease–a review for 2009”. Pediatric Radiology 3 (2009): 471-481.
  9. Sodhi KS., et al. “Rapid lung MRI in children with pulmonary infections: time to change our diagnostic algorithms”. Journal of Magnetic Resonance Imaging 43 (2016): 1196-1206.
  10. Sodhi KS., et al. “Rapid lung MRI: paradigm shift in evaluation of febrile neutropenia in children with leukemia: a pilot study”. Leuk Lymphoma 57 (2016): 70-75.
  11. Sodhi KS and Khandelwal N. “Magnetic resonance imaging of lungs as a radiation-free technique for lung pathologies immunodeficient patients”. Journal of Clinical Immunology 36 (2016): 621-623.
  12. Sodhi KS., et al. “Imaging of thoracic tuberculosis in children: current and future directions”. Pediatric Radiology 47 (2017): 1260-1268.
  13. Sodhi KS., et al. “Diagnostic Utility of 3T Lung MRI in Children with Interstitial Lung Disease”. Academic Radiology 3 (2018): 380-386.
  14. Bush A., et al. “ChILD-EU Collaboration. European protocols for the diagnosis and initial treatment of interstitial lung disease in children”. Thorax 70 (2015): 1078-1084.
  15. Braun S., et al. “Hydroxychloroquine in children with interstitial (diffuse parenchymal) lung diseases”. Pediatric Pulmonology 50 (2015): 410-419.
  16. Schrezenmeier E and Dorner T. “Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology”. Nature Reviews Rheumatology 16 (2020): 155-166.
  17. Thurm T., et al. “SFTPC mutations cause SP-C degradation and aggregate formation without increasing ER stress”. European Journal of Clinical Investigation 43 (2013): 791-800.
  18. Tomer Y., et al. “The common ABCA3E292V variant disrupts AT2 cell quality control and increases susceptibility to lung injury and aberrant remodelling”. The American Journal of Physiology-Lung Cellular and Molecular Physiology 321 (2021): L291-307.
  19. Kumrah R., et al. “Genetics of COPA syndrome”. The Application of Clinical Genetics 12 (2019): 11.
  20. Deterding R., et al. “Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease”. ERJ Open Research (2020): 7.
  21. Coclite D., et al. “Face mask use in the community for reducing the spread of COVID-19: a systematic review”. Frontiers in Medicine 7 (2020): 594269.
  22. Karim T., et al. “Interventions to prevent respiratory diseases-nutrition and the developing world”. Paediatric Respiratory Reviews 22 (2017): 31-37.
  23. Berthon BS and Wood LG. “Nutrition and respiratory health-feature review”. Nutrients 7 (2015): 1618-1643.

Mariam Mahmoud Hassan El Makkawy and Safwat Hassan Gad. Childhood Interstitial Lung Disease: What have we Learned So Far?. EC Paediatrics 12.1 (2023): 56-59.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net